Chengdu Olymvax Biopharmaceuticals Inc.

SHSE:688319 Stock Report

Market Cap: CN¥4.5b

Chengdu Olymvax Biopharmaceuticals Future Growth

Future criteria checks 3/6

Chengdu Olymvax Biopharmaceuticals is forecast to grow earnings and revenue by 82% and 12.5% per annum respectively. EPS is expected to grow by 81.3% per annum. Return on equity is forecast to be 7.6% in 3 years.

Key information

82.0%

Earnings growth rate

81.3%

EPS growth rate

Biotechs earnings growth42.8%
Revenue growth rate12.5%
Future return on equity7.6%
Analyst coverage

Low

Last updated11 Nov 2024

Recent future growth updates

No updates

Recent updates

Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Stock Rockets 40% As Investors Are Less Pessimistic Than Expected

Oct 09
Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Stock Rockets 40% As Investors Are Less Pessimistic Than Expected

We Think Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Has A Fair Chunk Of Debt

Sep 30
We Think Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Has A Fair Chunk Of Debt

What Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 26% Share Price Gain Is Not Telling You

Jun 24
What Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 26% Share Price Gain Is Not Telling You

Is There An Opportunity With Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 27% Undervaluation?

May 28
Is There An Opportunity With Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 27% Undervaluation?

Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely

Apr 18
Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely

These 4 Measures Indicate That Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Is Using Debt Extensively

Mar 26
These 4 Measures Indicate That Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Is Using Debt Extensively

Earnings and Revenue Growth Forecasts

SHSE:688319 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026703105N/A1591
12/31/202563160N/A531
12/31/202455739N/A951
9/30/2024530-9-257-7N/A
6/30/2024489-39-2177N/A
3/31/2024500-12-17512N/A
12/31/202349618-12644N/A
9/30/202352917-9593N/A
6/30/202354824-205-11N/A
3/31/202356137-206-15N/A
12/31/202254727-225-25N/A
9/30/202257370-191-98N/A
6/30/202255197-9513N/A
3/31/202247781-6817N/A
12/31/2021487108-3040N/A
9/30/202140578-2244N/A
6/30/202137865-1821N/A
3/31/202132850-384N/A
12/31/202032036-1821N/A
12/31/2019179-31-71-42N/A
12/31/201876-19-35-17N/A
6/30/20186314N/A-14N/A
3/31/2018547N/A-8N/A
12/31/2017451N/A-2N/A
9/30/201726-23N/A-21N/A
6/30/20177-48N/A-40N/A
3/31/20174-52N/A-41N/A
12/31/20160-56N/A-43N/A
9/30/20160-51N/A-37N/A
6/30/20160-47N/A-32N/A
3/31/20160-50N/A-29N/A
12/31/20150-52N/A-27N/A
12/31/20140-30N/A-20N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688319 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).

Earnings vs Market: 688319 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 688319 is expected to become profitable in the next 3 years.

Revenue vs Market: 688319's revenue (12.5% per year) is forecast to grow slower than the CN market (13.7% per year).

High Growth Revenue: 688319's revenue (12.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 688319's Return on Equity is forecast to be low in 3 years time (7.6%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 17:26
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chengdu Olymvax Biopharmaceuticals Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Yupeng JiaoChina Merchants Securities Co. Ltd.
Feifei XuChina Merchants Securities Co. Ltd.